Tecovirimat for the treatment of severe Mpox in Germany.
Germany
HIV
MSM
Mpox
Tecovirimat
Journal
Infection
ISSN: 1439-0973
Titre abrégé: Infection
Pays: Germany
ID NLM: 0365307
Informations de publication
Date de publication:
Oct 2023
Oct 2023
Historique:
received:
24
03
2023
accepted:
07
05
2023
medline:
3
10
2023
pubmed:
5
6
2023
entrez:
5
6
2023
Statut:
ppublish
Résumé
In May 2022, a multi-national mpox outbreak was reported in several non-endemic countries. The only licensed treatment for mpox in the European Union is the orally available small molecule tecovirimat, which in Orthopox viruses inhibits the function of a major envelope protein required for the production of extracellular virus. We identified presumably all patients with mpox that were treated with tecovirimat in Germany between the onset of the outbreak in May 2022 and March 2023 and obtained demographic and clinical characteristics by standardized case report forms. A total of twelve patients with mpox were treated with tecovirimat in Germany in the study period. All but one patient identified as men who have sex with men (MSM) who were most likely infected with mpox virus (MPXV) through sexual contact. Eight of them were people living with HIV (PLWH), one of whom was newly diagnosed with HIV at the time of mpox, and four had CD4+ counts below 200/µl. Criteria for treatment with tecovirimat included severe immunosuppression, severe generalized and/or protracted symptoms, a high or increasing number of lesions, and the type and location of lesions (e.g., facial or oral soft tissue involvement, imminent epiglottitis, or tonsillar swelling). Patients were treated with tecovirimat for between six and 28 days. Therapy was generally well-tolerated, and all patients showed clinical resolution. In this cohort of twelve patients with severe mpox, treatment with tecovirimat was well tolerated and all individuals showed clinical improvement.
Sections du résumé
BACKGROUND
BACKGROUND
In May 2022, a multi-national mpox outbreak was reported in several non-endemic countries. The only licensed treatment for mpox in the European Union is the orally available small molecule tecovirimat, which in Orthopox viruses inhibits the function of a major envelope protein required for the production of extracellular virus.
METHODS
METHODS
We identified presumably all patients with mpox that were treated with tecovirimat in Germany between the onset of the outbreak in May 2022 and March 2023 and obtained demographic and clinical characteristics by standardized case report forms.
RESULTS
RESULTS
A total of twelve patients with mpox were treated with tecovirimat in Germany in the study period. All but one patient identified as men who have sex with men (MSM) who were most likely infected with mpox virus (MPXV) through sexual contact. Eight of them were people living with HIV (PLWH), one of whom was newly diagnosed with HIV at the time of mpox, and four had CD4+ counts below 200/µl. Criteria for treatment with tecovirimat included severe immunosuppression, severe generalized and/or protracted symptoms, a high or increasing number of lesions, and the type and location of lesions (e.g., facial or oral soft tissue involvement, imminent epiglottitis, or tonsillar swelling). Patients were treated with tecovirimat for between six and 28 days. Therapy was generally well-tolerated, and all patients showed clinical resolution.
CONCLUSIONS
CONCLUSIONS
In this cohort of twelve patients with severe mpox, treatment with tecovirimat was well tolerated and all individuals showed clinical improvement.
Identifiants
pubmed: 37273167
doi: 10.1007/s15010-023-02049-0
pii: 10.1007/s15010-023-02049-0
pmc: PMC10240449
doi:
Substances chimiques
Benzamides
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1563-1568Informations de copyright
© 2023. The Author(s).
Références
Marennikova SS, Seluhina EM, Mal’ceva NN, Cimiskjan KL, Macevic GR. Isolation and properties of the causal agent of a new variola-like disease (monkeypox) in man. Bull World Health Organ. 1972;46(5):599–611.
pubmed: 4340219
pmcid: 2480798
Bunge EM, Hoet B, Chen L, Lienert F, Weidenthaler H, Baer LR, et al. The changing epidemiology of human monkeypox-A potential threat? A systematic review. PLoS Negl Trop Dis. 2022;16(2): e0010141.
doi: 10.1371/journal.pntd.0010141
pubmed: 35148313
pmcid: 8870502
Adler H, Gould S, Hine P, Snell LB, Wong W, Houlihan CF, et al. Clinical features and management of human monkeypox: a retrospective observational study in the UK. Lancet Infect Dis. 2022;22(8):1153–62.
doi: 10.1016/S1473-3099(22)00228-6
pubmed: 35623380
pmcid: 9300470
Reed KD, Melski JW, Graham MB, Regnery RL, Sotir MJ, Wegner MV, et al. The detection of monkeypox in humans in the Western Hemisphere. N Engl J Med. 2004;350(4):342–50.
doi: 10.1056/NEJMoa032299
pubmed: 14736926
Erez N, Achdout H, Milrot E, Schwartz Y, Wiener-Well Y, Paran N, et al. Diagnosis of imported Monkeypox, Israel, 2018. Emerg Infect Dis. 2019;25(5):980–3.
doi: 10.3201/eid2505.190076
pubmed: 30848724
pmcid: 6478227
Ng OT, Lee V, Marimuthu K, Vasoo S, Chan G, Lin RTP, et al. A case of imported Monkeypox in Singapore. Lancet Infect Dis. 2019;19(11):1166.
doi: 10.1016/S1473-3099(19)30537-7
pubmed: 31657773
pmcid: 7129797
Vaughan A, Aarons E, Astbury J, Balasegaram S, Beadsworth M, Beck CR, et al. Two cases of monkeypox imported to the United Kingdom, September 2018. Euro Surveill. 2018;23(38):1800509.
doi: 10.2807/1560-7917.ES.2018.23.38.1800509
pubmed: 30255836
pmcid: 6157091
Girometti N, Byrne R, Bracchi M, Heskin J, McOwan A, Tittle V, et al. Demographic and clinical characteristics of confirmed human monkeypox virus cases in individuals attending a sexual health centre in London, UK: an observational analysis. Lancet Infect Dis. 2022;22(9):1321–8.
doi: 10.1016/S1473-3099(22)00411-X
pubmed: 35785793
pmcid: 9534773
Philpott D, Hughes CM, Alroy KA, Kerins JL, Pavlick J, Asbel L, et al. Epidemiologic and clinical characteristics of Monkeypox cases—United States, May 17–July 22, 2022. MMWR Morb Mortal Wkly Rep. 2022;71(32):1018–22.
doi: 10.15585/mmwr.mm7132e3
pubmed: 35951487
pmcid: 9400536
World Health Organization (WHO). News release 23 July 2022. https://www.who.int/europe/news/item/23-07-2022-who-director-general-declares-the-ongoing-monkeypox-outbreak-a-public-health-event-of-international-concern .
World Health Organization (WHO). Multi-country outbreak of mpox. External Situation Report 18: https://www.who.int/publications/m/item/multi-country-outbreak-of-mpox--external-situation-report--18---16-march-2023 .
Tecovirimat—Summary of Product Characteristics: https://www.ema.europa.eu/en/documents/product-information/tecovirimat-siga-epar-product-information_en.pdf .
Grosenbach DW, Honeychurch K, Rose EA, Chinsangaram J, Frimm A, Maiti B, et al. Oral Tecovirimat for the Treatment of Smallpox. N Engl J Med. 2018;379(1):44–53.
doi: 10.1056/NEJMoa1705688
pubmed: 29972742
pmcid: 6086581
Desai AN, Thompson GR 3rd, Neumeister SM, Arutyunova AM, Trigg K, Cohen SH. Compassionate use of tecovirimat for the treatment of Monkeypox infection. JAMA. 2022;328(13):1348–50.
doi: 10.1001/jama.2022.15336
pubmed: 35994281
pmcid: 9396467
O’Laughlin K, Tobolowsky FA, Elmor R, Overton R, O’Connor SM, Damon IK, et al. Clinical use of tecovirimat (Tpoxx) for treatment of Monkeypox under an investigational new drug protocol—United States, May–August 2022. MMWR Morb Mortal Wkly Rep. 2022;71(37):1190–5.
doi: 10.15585/mmwr.mm7137e1
pubmed: 36107794
pmcid: 9484807
Merchlinsky M, Albright A, Olson V, Schiltz H, Merkeley T, Hughes C, et al. The development and approval of tecoviromat (TPOXX(®)), the first antiviral against smallpox. Antiviral Res. 2019;168:168–74.
doi: 10.1016/j.antiviral.2019.06.005
pubmed: 31181284
pmcid: 6663070
Mbrenga F, Nakouné E, Malaka C, Bourner J, Dunning J, Vernet G, et al. Tecovirimat for Monkeypox in Central African Republic under expanded access. N Engl J Med. 2022. https://doi.org/10.1056/NEJMc2210015 .
doi: 10.1056/NEJMc2210015
pubmed: 36449745
pmcid: 10117058
Norz D, Tang HT, Emmerich P, Giersch K, Fischer N, Schmiedel S, et al. Rapid adaptation of established high-throughput molecular testing infrastructure for Monkeypox virus detection. Emerg Infect Dis. 2022;28(9):1765–9.
doi: 10.3201/eid2809.220917
pubmed: 35905463
pmcid: 9423910
Nörz D, Brehm TT, Tang HT, Grewe I, Hermanussen L, Matthews H, et al. Clinical characteristics and comparison of longitudinal qPCR results from different specimen types in a cohort of ambulatory and hospitalized patients infected with monkeypox virus. J Clin Virol. 2022;155:105254.
doi: 10.1016/j.jcv.2022.105254
pubmed: 36057206
pmcid: 9528238
Hermanussen L, Grewe I, Tang HT, Nörz D, Bal LC, Pfefferle S, et al. Tecovirimat therapy for severe monkeypox infection: longitudinal assessment of viral titers and clinical response pattern-A first case-series experience. J Med Virol. 2022. https://doi.org/10.1002/jmv.28181 .
doi: 10.1002/jmv.28181
pubmed: 36177717
Boesecke C, Monin MB, van Bremen K, Schlabe S, Hoffmann C. Severe monkeypox-virus infection in undiagnosed advanced HIV infection. Infection. 2022;50(6):1633–4.
doi: 10.1007/s15010-022-01901-z
pubmed: 35969365
pmcid: 9705473
Schlabe S, Boesecke C, Isselstein J. Ulcer at corner of mouth as first sign of infection with Monkeypox virus. Dtsch Arztebl Int. 2022;119(29–30):511.
pubmed: 36345587
pmcid: 9669326
Brehm TT, Hermanussen L, Schmiedel S. Orthopox simiae muscle abscess. Infection. 2022. https://doi.org/10.1007/s15010-022-01961-1 .
doi: 10.1007/s15010-022-01961-1
pubmed: 36472781
pmcid: 10205884
Mitja O, Alemany A, Marks M, Lezama Mora JI, Rodriguez-Aldama JC, Torres Silva MS, et al. Mpox in people with advanced HIV infection: a global case series. Lancet. 2023;401(10380):939–49.
doi: 10.1016/S0140-6736(23)00273-8
pubmed: 36828001
Wittner M, Schlicker V, Libera J, Bockmann JH, Horvatits T, Seiz O, et al. Comparison of the integrin alpha4beta7 expression pattern of memory T cell subsets in HIV infection and ulcerative colitis. PLoS ONE. 2019;14(7): e0220008.
doi: 10.1371/journal.pone.0220008
pubmed: 31356607
pmcid: 6663001
Hawkins RA, Rank RG, Kelly KA. Expression of mucosal homing receptor alpha4beta7 is associated with enhanced migration to the Chlamydia-infected murine genital mucosa in vivo. Infect Immun. 2000;68(10):5587–94.
doi: 10.1128/IAI.68.10.5587-5594.2000
pubmed: 10992458
pmcid: 101510
Cicala C, Martinelli E, McNally JP, Goode DJ, Gopaul R, Hiatt J, et al. The integrin alpha4beta7 forms a complex with cell-surface CD4 and defines a T cell subset that is highly susceptible to infection by HIV-1. Proc Natl Acad Sci U S A. 2009;106(49):20877–82.
doi: 10.1073/pnas.0911796106
pubmed: 19933330
pmcid: 2780317
Kelly KA, Chan AM, Butch A, Darville T. Two different homing pathways involving integrin beta7 and E-selectin significantly influence trafficking of CD4 cells to the genital tract following Chlamydia muridarum infection. Am J Reprod Immunol. 2009;61(6):438–45.
doi: 10.1111/j.1600-0897.2009.00704.x
pubmed: 19392981
pmcid: 2888875
Heinrich F, Nentwich MF, Bibiza-Freiwald E, Norz D, Roedl K, Christner M, et al. SARS-CoV-2 blood RNA load predicts outcome in critically ill COVID-19 patients. Open Forum Infect Dis. 2021;8(11):ofab509.
doi: 10.1093/ofid/ofab509
pubmed: 34796247
pmcid: 8522363
Malsy J, Veletzky L, Heide J, Hennigs A, Gil-Ibanez I, Stein A, et al. Sustained response after remdesivir and convalescent plasma therapy in a B cell-depleted patient with protracted coronavirus disease 2019 (COVID-19). Clin Infect Dis. 2021;73(11):e4020–4.
doi: 10.1093/cid/ciaa1637
pubmed: 33103195
Norz D, Pfefferle S, Brehm TT, Franke G, Grewe I, Knobling B, et al. Evidence of surface contamination in hospital rooms occupied by patients infected with monkeypox, Germany, June 2022. Euro Surveill. 2022. https://doi.org/10.2807/1560-7917.ES.2022.27.26.2200477 .
doi: 10.2807/1560-7917.ES.2022.27.26.2200477
pubmed: 35775427
pmcid: 9248266